In individuals with metabolic syndrome or obesity, circulating FGF19 levels are reduced, whereas CYP7A1 expression and total bile acid pool size are increased in type 2 diabetes, suggesting disruption of the negative FXR/FGF19 feedback loop [147]. This evidence concerns the gene FGF19 and metabolic syndrome.